Development of a pilot scale process for the anti-alzheimer drug (-)-galanthamine using large-scale phenolic oxidative coupling and crystallisation-induced chiral conversion

Organic Process Research and Development

Volumn 3, Issue 6, 1999, Pages 425-431

  Küenburg, Bernhard ^a   Czollner, Laszlo ^a   Frôhlich, Johannes ^b   Jordis, Ulrich ^b  

^a Sanochemia AG   (Austria)

^b VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033479347     PISSN: 10836160     EISSN: None     Source Type: Journal    
DOI: 10.1021/op990019q     Document Type: Article

References (6)

1. Chistoni, G.; Guaraldi, G. P. Riv. Neuropsichiatr. Sci. Affini (Parma) 1960, 6, 53.
2. Göppel, W.; Betram, W. Psychiatr. Neurol. Med. Psychol. 1971, 23, 712.
3. Mayrhofer, O. South. Med. J. 1966, 59, 1364.
4. Baraka, A.; Sami Harik, M. D. JAMA, J. Am. Med. Assoc. 1977, 238, 2293.
5. Mucke, H. A. M. Drugs Future 1997, 33, 259.
6. Rainer, M. Drugs Today 1997, 33, 273.